author-photo

Corrado Gallo Stampino

Pfizer

15

Papers

260

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib ‘On Target’ Adverse Events

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Abstract LB-229: A phase 1 open-label fixed-sequence two-period crossover study of the effect of multiple doses of tamoxifen on palbociclib (PD-0332991) pharmacokinetics in healthy male volunteers

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (18)
Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial)

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD).

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC).

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting

2012 Journal of Biological Chemistry
Show All
- Source
- Cite
- Save
Citations (80)
Abstract A1: Phase 1 study of PF-03446962, a fully human mAb against activin receptor-like kinase 1 (ALK 1), a TGFβ receptor involved in tumor angiogenesis.

2011 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (4)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (104)
Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF{beta} receptor involved in tumor angiogenesis.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)